2016 American Transplant Congress
Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.
On Behalf of the CTOT11 Consortium, Brigham & Women's Hospital, Boston, MA.
PurposeThe NIH-funded study CTOT11: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RIT) Therapy in Cardiac Transplantation, was a randomized clinical trial in non-sensitized primary heart…2016 American Transplant Congress
Comparison of Actual versus Goal Tacrolimus Levels Post Cardiothoracic Transplant.
Vanderbilt Transplant Center, Nashville, TN.
BackgroundAlthough target tacrolimus (TAC) trough levels necessary to prevent rejection are established post heart/lung transplant (tx), there is little published literature on the proportion of…2016 American Transplant Congress
Fatty Liver in Non-Hepatic Organ Transplantation.
Tampa General Medical Group, Tampa, FL.
With the availability of effective antiviral regimen for HCV, Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western countries and…2016 American Transplant Congress
Cytomegalovirus Infection After Cardiac Transplantation.
University of British Columbia, Vancouver, Canada.
BackgroundOrthotopic heart transplantation (OHT) continues to be the gold standard for the management of patients with end-stage heart failure. However, complications following OHT may result…2016 American Transplant Congress
The Increase of Serum MiR-142-3p Level in Acute Cardiac Rejection as a Reflection of Exosome-Mediated Genetic Exchange Between T Cells and Endothelial Cells.
1Cardiology, Lund University, Lund, Sweden; 2PROOF Center of Excellence, Vancouver, Canada.
IntroductionIn the recent years, microRNAs has emerged as the popular biomarker candidate in the field of solid organ transplantation due to their expression patterns reflect…2016 American Transplant Congress
Necroptosis Is Involved in CD4+ T-Cell Mediated Microvascular Endothelial Cell Death and Chronic Cardiac Allograft Rejection.
Heart transplantation is potentially the only viable option for patients with end-stage heart failure. Despite advances in immunosuppressive therapies, cardiac allograft chronic rejection is a…2016 American Transplant Congress
CMV-Accelerated Cardiac Allograft Rejection Is Associated with Dysregulation of Sphingolipid Metabolomics.
PurposeCytomegalovirus (CMV) infection accelerates transplant vascular sclerosis (TVS) and chronic rejection (CR) in solid organ transplants. Sphingolipid metabolism plays an immunomodulatory role in transplant rejection,…2016 American Transplant Congress
The Impact of Sequential Gene Modifications on Cardiac Xenograft Survival.
1CSRP, NHLBI/NIH, Bethesda, MD; 2DVR / ORS, NIH, Bethesda, MD; 3Revivicor, Inc, Blacksburg, VA.
Introduction: One of the major advances in xenotransplantation is the ability to modify donor pig genetics. Using rapidly evolving techniques of pig cloning and gene…2016 American Transplant Congress
Anti-BTLA Antibody (6B2) Induced Prolongation of Fully MHC-Mismatched Murine Cardiac Allograft and Generation of Foxp3+ Regulatory T Cells.
Background: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important…2016 American Transplant Congress
Inclusion of Human Tissue Factor Pathway Inhibitor or Thrombomodulin Transgenes Attenuates Critical Consumptive Thrombocytopenia in Cardiac Xenotransplantation.
ObjectiveA major obstacle in the success of cardiac xenotransplantation has been the development of significant consumptive thrombocytopenia, frequently limiting recipient survival. Advances in genetic engineering…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- Next Page »